Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | BRD4 | O60885 | 1/20 | 0.63 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.63 |
| ▸ | OGG1 | O15527 | 5/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20733336 | 0.85 | RAB9A (0.69) | RAB9ANPC1BRD4ATAD2OGG1 | |
| SCHEMBL20733380 | 0.81 | OGG1 (0.67) | RAB9ANPC1BRD4ATAD2OGG1 | |
| SCHEMBL20733385 | 0.78 | RAB9A (0.69) | RAB9ANPC1BRD4ATAD2OGG1 | |
| SCHEMBL17117541 | 0.78 | BRD4 (0.71) | RAB9ANPC1BRD4ATAD2OGG1 | |
| SCHEMBL16771416 | 0.78 | BRD4 (1.00) | RAB9ANPC1BRD4ATAD2OGG1 | |
| SCHEMBL22104625 | 0.77 | OGG1 (0.83) | RAB9ANPC1BRD4ATAD2OGG1 | |
| SCHEMBL22104657 | 0.75 | OGG1 (0.74) | RAB9ANPC1BRD4ATAD2OGG1 | |
| SCHEMBL22104699 | 0.75 | OGG1 (0.77) | RAB9ANPC1BRD4ATAD2OGG1 | |
| SCHEMBL22104718 | 0.75 | OGG1 (0.74) | RAB9ANPC1BRD4ATAD2OGG1 | |
| SCHEMBL17005768 | 0.75 | SYK (0.62) | RAB9ANPC1BRD4ATAD2OGG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200190034-A1 | Inhibitors of Base Excision Repair Activity and Therapeutic Methods Based Thereon | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190034-A1 | Inhibitors of Base Excision Repair Activity and Therapeutic Methods Based Thereon | OGG1, UNG, MPG | RAB9A 2658/4885NPC1 3192/4885BRD4 2493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.